Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Heterodimeric IL-15 in Cancer Immunotherapy

(2021) Cristina Bergamaschi et al.   Cancers

Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy

(2021) Fredrik Barrenäs et al.   PLoS Pathogens

Rationale for IL-15 superagonists in cancer immunotherapy

(2020) Karin M. Knudson et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer

(2020) Katsuyuki Tanabe et al.   MEDICINE

IL-15 in the Combination Immunotherapy of Cancer

(2020) Thomas A. Waldmann et al.   Frontiers in Immunology

Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10

(2020) Cristina Bergamaschi et al.   Journal for ImmunoTherapy of Cancer

IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion

(2019) Kevin C Conlon et al.   CLINICAL CANCER RESEARCH

Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer

(2019) Thomas A. Waldmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

(2018) Rizwan Romee et al.   BLOOD

Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques

(2018) Cristina Bergamaschi et al.   CYTOKINE

IL-2 and Beyond in Cancer Immunotherapy

(2018) John M. Wrangle et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes

(2018) Dionysios C. Watson et al.   PLoS Pathogens

The potential and promise of IL-15 in immuno-oncogenic therapies

(2017) Tanya O. Robinson et al.   IMMUNOLOGY LETTERS

Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion

(2016) Sinnie Sin Man Ng et al.   CLINICAL CANCER RESEARCH

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

(2016) D. A. Vallera et al.   CLINICAL CANCER RESEARCH

A simple tube adapter to expedite and automate thawing of viably frozen cells

(2016) Margaret Beddall et al.   JOURNAL OF IMMUNOLOGICAL METHODS

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

(2016) Peter S. Kim et al.   Oncotarget

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

(2016) J. Naidoo et al.   Cancer Immunology Research

The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas

(2015) M. Rosario et al.   CLINICAL CANCER RESEARCH

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

(2015) Kevin C. Conlon et al.   JOURNAL OF CLINICAL ONCOLOGY

The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy

(2015) T. A. Waldmann   Cancer Immunology Research

Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells

(2014) C Bergamaschi et al.   GENE THERAPY

Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action

(2014) S. Dubois et al.   JOURNAL OF IMMUNOLOGY

Characterization and Favorablein VivoProperties of Heterodimeric Soluble IL-15·IL-15Rα Cytokine Compared to IL-15 Monomer

(2013) Elena Chertova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Circulating IL-15 exists as heterodimeric complex with soluble IL-15R  in human and mouse serum

(2012) C. Bergamaschi et al.   BLOOD

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs  -Cell Function

(2012) S. A. Long et al.   DIABETES

Augmented IL-15R  Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice

(2012) M. Zhang et al.   JOURNAL OF IMMUNOLOGY

Secretion and Biological Activity of Short Signal Peptide IL-15 Is Chaperoned by IL-15 Receptor Alpha In Vivo

(2009) C. Bergamaschi et al.   JOURNAL OF IMMUNOLOGY

Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

(2009) M. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin-15/Interleukin-15R  Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells

(2008) M. Epardaud et al.   CANCER RESEARCH

IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation

(2008) Erwan Mortier et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells

(2008) Thomas Y. Wuest et al.   JOURNAL OF LEUKOCYTE BIOLOGY